Cost-Effectiveness of Systematic Screening and Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) in United States medrxiv.org/content/10.1101/20

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.